VivoSeq
Oncology

Chondrosarcoma

23

Pipeline Programs↗

7

Active Trials↗

18

Companies Involved↗

Chondrosarcoma is an emerging landscape with 23 programs across 18 companies. The most active players are Pfizer, Roche, Gynecologic Oncology Group. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

75/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1Roche logo

Roche

3 programs

Phase 2G

Gynecologic Oncology Group

2 programs

Phase 2I

Inhibrx Biosciences, Inc

1 program

Phase 2I

Infinity Pharmaceuticals, Inc.

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

19 of 23 classified programs — the dominant modality here.

17%ALL OTHERSProtein / enzyme313%Monoclonal antibody14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Active, not recruiting5 · 33%
Recruiting2 · 13%
Terminated1 · 7%
Suspended1 · 7%

Clinical Trials

Trial Activity

15 trials

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05193188·70 enrolled
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Recruiting·SServier Bio-Innovation LLC·Phase 3·NCT06127407·136 enrolled
Study of INBRX-109 in Conventional Chondrosarcoma
Active, not recruiting·IInhibrx Biosciences, Inc·Phase 2·NCT04950075·206 enrolled
Vismodegib in Treating Patients With Advanced Chondrosarcomas
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT01267955·45 enrolled
AG-120 in People With IDH1 Mutant Chondrosarcoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04278781·6 enrolled
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04340843·19 enrolled
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Active, not recruiting·—·Phase 1·NCT03173976·17 enrolled
Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
Completed·IItalian Sarcoma Group·Phase 2·NCT00928525·35 enrolled
Apatinib for Inoperable Advanced Chondrosarcoma
Completed·PPeking University People's Hospital·N/A·NCT04260113·40 enrolled
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
Completed·SWOG Cancer Research Network·Phase 2·NCT00107419·75 enrolled
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Completed·EEmerald Clinical Inc.·Phase 2·NCT01330966·47 enrolled
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
Completed·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT01310816·105 enrolled
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00073983·54 enrolled
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas
Suspended·CCentre Leon Berard·Phase 2·NCT02008019·57 enrolled
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Terminated·Roche logoRoche·Phase 2·NCT00543712·15 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)